Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), namely palbociclib, ribociclib, and abemaciclib, have become a cornerstone in the treatment of hormone-receptor-positive, HER2-negative advanced breast cancer, markedly improving progression-free survival and, in certain settings, overall survival. The gene discussed is CDK4; the disease is breast cancer.